Combining HLA-DQ-gluten tetramers with mass cytometry and RNA sequencing analysis, we find that gluten-specific CD4 + T cells in the blood and intestines of patients with celiac disease display a surprisingly rare phenotype. Cells with this phenotype are also elevated in patients with systemic sclerosis and systemic lupus erythematosus, suggesting a way to characterize CD4 + T cells specific for disease-driving antigens in multiple autoimmune conditions.
Celiac disease (CeD) is a human leukocyte antigen (HLA)-DQ2/ HLA-DQ8-associated autoimmune enteropathy driven by the activation of gluten-specific CD4 + T lymphocytes upon gluten consumption 1 . We combined gluten peptide-HLA class II tetramers with a 43-parameter antibody panel for mass cytometry analysis (Extended Data Figs. 1 and 2 and Supplementary Table 1). We found that cells binding to these tetramers, representing five gluten peptides complexed to HLA-DQ2.5 (Supplementary Table 2 ), cluster within a surprisingly narrow subset of small intestinal CD4 + T cells in HLA-DQ2.5
+ patients with untreated CeD and comprise 0.3-1.5% of the total (Fig. 1a ,b and participants: Supplementary Table 3 ). These gut T cells expressed multiple activation markers (C-X-C chemokine receptor type 3 (CXCR3), CD38, CD161, CD28, HLA-DR and OX40 (also known as TNFRSF4)) as well as CD39 and programmed cell death protein 1 (PD-1), suggestive of chronic activation, whereas are negative for the exhaustion marker killer cell lectin-like receptor subfamily G member 1 (KLRG1) (Fig. 1c- Fig. 3) . Importantly, the transcriptional profile of these tetramer-positive CD4 + gut T cells correlates highly with the surface marker expression ( Fig. 1f and Extended Data Fig. 4 ).
In addition, RNA sequencing (RNA-seq) analysis demonstrated that CD200, CD84, C-X-C motif chemokine 13 (CXCL13) and interleukin-21 (IL-21) are transcribed as well ( Fig. 1g and the complete list in Supplementary Table 5 ). These markers are characteristic of follicular B helper T cells, except that CXCR5 was not detectable on the surface of tetramer-positive gut T cells (Fig. 1c-e) , despite some transcription (Fig. 2f ). Relevant to this, it was recently demonstrated that CD4
− cells, of unknown antigen specificity, are expanded in the synovium of seropositive patients with rheumatoid arthritis and express a similar phenotype to what we report here, including expression of CD200, CXCL13, IL-21, PD-1, inducible T-cell costimulator (ICOS), OX40 and CD28 (ref.
2 ). The authors speculated that these cells induce plasma cell differentiation in the inflamed tissue. In general, T cell-induced plasma cell differentiation should show signs of proliferation and, with respect to the gluten-specific CD4 + T cells analyzed here, the proliferation marker Ki-67 was expressed in the blood (13-98%) but not in the gut (Fig. 1h,i) . Conceivably, gluten-specific T cells in CeD can promote the production of disease-specific antibodies to transglutaminase 2 and deamidated gluten peptides 3 . Our findings here, together with previous reports showing that these disease-specific gut plasma cells are negative for Ki-67 (refs. 4, 5 ), indicate that the disease-relevant T cells and B cells initially interact and proliferate outside the celiac lesion. Once entering the gut, T cells may interact with plasma cells via the plasma cell presentation of gluten T cell epitopes 6 and influence the microenvironment. IL-21 is a key cytokine for plasma cells 7 and intraepithelial lymphocytes 8 , both of which are increased in the celiac gut lesion 1, 4 . Although the relationship between lymphocytes in the blood versus those in tissues is frequently a question, here, we find that gluten tetramer-binding T cells in the blood of patients with untreated CeD largely expresses the same pattern of markers as in the gut (CXCR3 . Furthermore, despite Ki-67 expression (Fig. 1h,i) , only a small fraction of the tetramer-positive cells in the blood expressed CXCR5 (confirmed by FACS in Extended Data Fig. 6 ) and thus do not express a classical follicular T helper cell phenotype. As previously observed [9] [10] [11] , the tetramer-binding cells were almost exclusively effector memory cells (CD45RA − and CD62L Data Fig. 7c ). In addition, although some gluten-specific cells express Foxp3, these cells were CD25 − (Extended Data Fig. 7d-g ). Thus, gluten-specific T cells in vivo do not express a classical regulatory T cell phenotype.
We next asked whether antigenic stimulation drives these CD4 + T cells. This involved a 3-day oral gluten challenge in five patients with CeD (previously on a gluten-free diet), which is known to mobilize preexisting clones of gluten-specific and gut-homing T cells into the blood on day 6 (refs. 10, 13 ). Upon challenge, these cells upregulated markers expressed by gluten-specific cells in the patients with untreated celiac, including CD38, CD39, CXCR3, PD-1, ICOS, CD161, C-C chemokine receptor type 5 (CCR5) and CD28 (Fig. 2f) . These cells clustered in close proximity to tetramerbinding cells in untreated CeD (Fig. 2g) , differing chiefly by higher CCR5 and lower CD39 expression after the gluten challenge. Taken together, specific antigen stimulation in vivo prompts gluten-specific T cells with an almost identical phenotype as those typical of untreated CeD.
To characterize the CD4 + T cells in patients with other autoimmune conditions, we performed mass cytometry analysis in peripheral blood mononuclear cells (PBMCs) of patients with systemic sclerosis and systemic lupus erythematosus, together with CeD subjects and presumably healthy blood bank donors (participants: Supplementary Table 6 and antibody panel: Supplementary Table 7) . We also included subjects suffering from acute influenza infection for comparison purposes. Unsupervised clustering of activated (CD38 + ), memory (CD45RA − ) CD4 + blood T cells showed that, unlike in CeD and the two other autoimmune conditions, the influenza response was dominated by a CD161
− subset (Fig. 2h ), which faded with disease recovery and was very low in the other samples (Extended Data Fig. 8 ). We then tested whether an unbiased estimation (Extended Data Fig. 9 ) would report elevated levels of cells with the gluten-specific T cell phenotype profile in these disease states. Strikingly, we found that seven out of eight patients with untreated CeD, eight out of ten patients with systemic sclerosis and four out of ten patients with systemic lupus erythematosus had significantly elevated numbers of CD4 + T cells with this phenotype compared to controls (Fig. 2i) . Manual gating gave similar results (Extended Data Fig. 10 ), and we conclude that this subset is elevated in many patients with these types of autoimmunity. Although four out of seven influenza-infected individuals also showed elevated numbers of CD4 + T cells with the phenotype displayed by glutenspecific cells, this was only a minor part of an influenza response (median < 2% versus 20% constituted by the CD161
− subset; Fig. 2h and Extended Data Fig. 8 ). It is nonetheless intriguing that CD4 + T cells with the unique phenotype of gluten-specific cells are elevated not only in autoimmune conditions but also transiently during the acute phase of a viral infection. We speculate that these cells, unlike the CD161 − /CD39 − cells, may represent self-antigenspecific T cell clones that cross-react with influenza antigens, as suggested by the abundance of self-specific cells in healthy humans 14 and their propensity for cross-reactivity 15 .
In conclusion, CeD is the only human autoimmune disease in which the causative antigen is known, despite decades of effort in other systems. Here, our results, combined with similar findings in rheumatoid arthritis 2 , strongly suggest that there is a distinct and relatively rare type of CD4 + T lymphocytes that is common to multiple autoimmune disorders and transiently in at least one viral infectious disease. As we know that most or all of the gluten-specific T cells are in this subset in patients with CeD, it is reasonable to imagine that these cells might also be the key disease-driving T cells in other autoimmune diseases. + blood T cells and occurrence of a similar subset in other immune conditions. a, HLA-DQ2.5:gluten tet staining with mass cytometry for a patient with UCeD and control subject. b, t-SNE plots with CD4
+ blood T cells of a patient with UCeD and control subject. c, Expression of proteins on tet
+ blood T cells of a patient with UCeD. d, Heat map with absolute expression (staining intensity) of tet + cells. e, log 2 fold change for tet + versus pre-tet-enriched CD4 + T cells. n = 7 patients with UCeD, 10 control subjects, 9 experiments (a-e). f, log 2 fold-change expression of indicated markers for tet + CD4 + blood T cells before versus following gluten challenge of five patients with treated CeD (TCeD) and versus tet + cells of seven patients with UCeD (same patients with UCeD in d and e). g, t-SNE plot with tet − and tet + cells in a TCeD subject before and following gluten challenge compared to tet + of an UCeD subject. Three representative experiments are shown in f and g. h, t-SNE plots and unsupervised clustering of activated (CD38 + ) memory (CD45RA − ) CD4 + blood T cells in the indicated participant groups (n = 5 distinct samples in each group) and tet + cells of seven patients with UCeD. Cluster 1, containing 75% of tet + cells from patients with UCeD, and cluster 2, upregulated in subjects with influenza infection (Extended Data Fig. 8 ), are color coded. i, Unbiased prevalence estimate among the indicated participant groups (19 experiments) for cells with the same phenotype profile as tet + cells in patients with UCeD, using a supervised classification model (Extended Data Fig. 8) . P values were calculated with an unpaired, two-tailed t-test. The median frequency, interquartile range and maximum/minimum whiskers are shown for the box plots. SLE, systemic lupus erythematosus. . The histological appearance in the duodenal mucosa was graded according to the Marsh score: normal mucosa (Marsh score 0), increased number of intraepithelial lymphocytes (Marsh score 1), hyperplastic lesion and crypt hyperplasia (Marsh score 2) and various degree of villous atrophy (Marsh score 3A-C) 17, 18 . The studies on patient material obtained from subjects examined at Oslo University Hospital during routine follow-up were approved by the Regional Committee for Medical and Health Research Ethics South-East Norway (2010/2720). Patients with treated CeD who were challenged with gluten received one in-house-produced cookie containing 10 g of enriched flour (Validus AS) each day for 3 days and blood samples were taken on day 6 after gluten challenge when a peak in the frequency of gluten-specific CD4 + blood T cells was expected 10, 19 ( All the included participants also tested negative with the same swab test for influenza B virus, parainfluenza 1, 2 and 3 viruses, metapneumovirus and rhinovirus. Included participants were examined again 23 to 41 days after their initial medical examination and inclusion. One of the seven included patients did not donate blood at this second consultation. Influenza-associated symptoms of participants from the influenza cohort were documented on a patient diary and were evaluated by a research nurse at inclusion and during the follow-up visit. The definition of infection recovery was based on the resolution of influenza-like symptoms at the follow-up visit. Our study cohort of patients with autoimmune disorders other than CeD did not receive immunomodulating treatment at the time of blood draw and met classification criteria for systemic sclerosis 20 or systemic lupus erythematosus 21 , respectively. The recruitment of these patients was covered by the Regional Committee for Medical Research Ethics in SouthEast Norway (2016/119) and IRB 14734 (Stanford University Immunological and Rheumatic Disease Database: Disease Activity and Biomarker Study). Buffy coats were obtained from anonymous blood donors at the Stanford Blood Center or Oslo University Hospital (blood bank).
Author contributions
We isolated PBMCs through density gradient centrifugation (Lymphoprep, Axis Shield). Duodenal biopsies were treated 2 × 10 min with 2 mM EDTA + 2% FCS in PBS at 37 °C to remove the epithelial layer prior to further digestion with collagenase (1 mg ml −1 ) in 2% FCS in PBS at 37 °C for 60 min. The samples were then homogenized using a 1.2-mm syringe and filtered through a 40-μm or 70-μm cell strainer to obtain single-cell suspensions. All samples were cryopreserved.
HLA class II tetramer staining and mass cytometry. The protocol established here was partially derived from protocols on a combination of HLA class-I tetramers and mass cytometry 22, 23 . We thawed the frozen cell samples in 20% FCS in RPMI and washed the cells in 10% FCS with Benzonase (Sigma-Aldrich/ Merck, 1:10,000) in RPMI before resuspending and counting the cells in CyFACS buffer (0.1% BSA, 2 mM EDTA and 0.05% sodium azide in PBS). After 450g centrifugation, cells were treated with 1:10 diluted FcR block (Miltenyi Biotek), stained with anti-CD11c, anti-CD14 and 5 μg ml −1 purified anti-CD32 (clone FUN-2) to reduce nonspecific tetramer binding, and barcoded with anti-CD45 coupled with 89Y or 108Pd 24 in 200 μl CyFACS buffer. Only names and staining concentrations of monoclonal antibodies that are not listed in Supplementary  Tables 1 and 7 are specified here. After one wash step, the samples from patients with CeD were stained for 40 min at room temperature with HLA-DQ2.5:gluten tetramers representing the five different disease-relevant and immunodominant gluten T cell epitopes 25 -DQ2.5-glia-α1a, DQ2.5-glia-α2, DQ2.5-glia-ω1, DQ2.5-glia-ω2 and DQ2.5-hor3 (Supplementary Table 3 )-at 15 μg ml −1 each in 200 μl CyFACS buffer, in the case of peripheral blood mononuclear cells (PBMCs), or 100 μl CyFACS buffer, in the case of biopsy-derived single-cell suspensions. We also added tetramers representing HLA-DQ2.5:CLIP2 at a concentration of 20 μg ml −1 to exclude tetramer background staining (Extended Data Fig. 1d ). HLA-DQ2.5:gluten and HLA-DQ2.5:CLIP2 molecules were produced as previously described 26 and, 2 h before cell staining, multimerized on phycoerythrin (PE)-cyanine7 (Cy7)-coupled streptavidin or allophycocyanin (APC)-Cy7-coupled streptavidin, respectively (Thermo Fisher Scientific). The cells were washed and tetramer-binding cells were metal tagged with 1.25 μl anti-PE and 1.25 μl antiphycocyanin for 20 min on ice in 100 μl CyFACS buffer followed by another , and is visualized in Fig. 1c) . The cells were washed and 2% of the PBMCs of patients with CeD (pre-tetramer-enriched sample) were removed and added to 1 million CD45-barcoded carrier cells of a healthy donor to reduce cell loss and left on ice until further staining. The remaining PBMCs of patients with CeD were enriched for tetramer-binding cells on a magnetized LS column (Miltenyi Biotec). We then added 1 million CD45-barcoded PBMCs from a healthy donor to the tetramer-enriched sample (and to the biopsy-derived single-cell suspensions that had not undergone tetramer enrichment), and washed the cells once before all samples were stained for 20 min on ice with a panel of metal-coupled antibodies (Supplementary Table 1 or in the case of participants included in Extended Data Fig. 10e,f; Supplementary Table 7) . After one wash step, the cells were stained for 5 min at room temperature with cisplatin (Fluidigm) at 1/1,500 concentration and washed before overnight incubation at 4 °C with 1:1,000 diluted 125 μM DNA intercalator in Maxpar Fix and Perm Buffer (Fluidigm). The following day, we washed the cells in CyFACS buffer, PBS and milli-Q water (1× each) before they were analyzed in milli-Q water using a Helios instrument (Fluidigm). Unlike in the gut samples analyzed here and in previous studies on gluten-specific cells in the blood using flow cytometry 9, 27 , we have not specified the frequency of tetramer-binding cells in the blood analyzed with mass cytometry as washing, resuspension in water and mass cytometer tubing considerably reduced the number of cells (including tetramer-binding cells) in the tetramer-enriched sample relative to the total number of CD4 + T cells in the sample. Prior to the establishment of the protocol, we also used fluorescein-coupled streptavidin (BioLegend) and anti-fluorescein 160Gd (Fluidigm) (Extended Data Fig. 1a ) and the gluten-specific T cell clone TCC1030.43 derived from the blood of patients with CeD 9 to determine which fluorophore generated the best staining intensity through secondary metal-tagged antibody staining. In each experiment, we stained a gluten-specific T cell clone with the corresponding HLA-DQ2.5:gluten tetramer as a positive control for tetramer staining with mass cytometry. The T cell clones used to establish and validate the HLA class II tetramer staining with mass cytometry can be provided on request after completion of a material transfer agreement.
Flow cytometric analysis. We prepared and stained CeD blood and biopsy material including T cell clones with HLA-DQ2.5:gluten tetramers and surface markers according to protocols described elsewhere 9, 13 . One patient with CeD analyzed with flow cytometry was HLA-DQ8 + /HLA-DQ2.5 − , and for this subject, we used HLA-DQ8:gluten tetramers representing the two gluten epitopes HLA-DQ8-glia-α1 and HLA-DQ8-glia-γ1b 28 . Tetramer-sorted cells were cultured in vitro as previously described 29 . Staining for Ki-67 and Foxp3 was performed according to the manufacturer's protocol (Thermo Fisher Scientific's eBioscience Foxp3/Transcription Factor Staining Buffer Set). Antibodies used for flow cytometry staining are listed in Supplementary Table 8 . The cells were analyzed with a LSR II instrument or sorted on a FACS Aria II instrument (BD Bioscience).
RNA-seq analysis. Single-cell suspension of duodenal biopsies from five patients with CeD and four healthy subjects (Supplementary Table 3) were stained with PE-conjugated HLA-DQ2.5:gluten tetramers representing four immunodominant T cell epitopes of gluten: DQ2.5-glia-α1a, DQ2.5-glia-α2, DQ2.5-glia-ω1 and DQ2.5-glia-ω2 (ref. Table 2 ), as previously described 30 . Following tetramer staining, the cells were labeled with anti-CD3 BV570 (BioLegend), anti-CD4 APC-H7 (BD Biosciences), anti-CD14 Pacific Blue (BioLegend), anti-CD11c Horizon V450 (BD Bioscience), anti-CD27 PE-Cy7 (eBioscience), IgA FITC (Southern Biotech) and Live/Dead Fixable Violet Dead Cell Stain (Thermo Fisher Scientific). See also the Nature Research Reporting Summary for more details on the antibodies used. We added anti-CD27 and anti-IgA owing to a parallel study on a different cell subset. HLA-DQ2.5:gluten tetramer-positive and tetramer-negative CD4 + T cells were sorted in two separate tubes using FACS Aria II (BD Bioscience). RNA was extracted using RNeasy Micro Kit (Qiagen) and quantified on a 2100 Bioanalyzer using a RNA 6000 Pico Kit (Agilent Technologies).
) (Supplementary
Approximately 90 ng RNA was used for cDNA synthesis and amplification. cDNA synthesis was performed at 42 °C for 90 min and 70 °C for 10 min. cDNA was amplified with these PCR conditions: 95 °C for 1 min; followed by 15 cycles (98°C for 10 s; 65 °C for 30 s; and 68 °C for 3 min) and 72 °C for 10 min using the SMARTer Ultra Low Input RNA Kit for Sequencing v3 (Clontech Laboratories). Amplified cDNA was quantified using the High Sensitivity DNA Kit (Agilent Technologies). Tagmentation and adapter ligation were achieved using the Nextera XT library preparation kit (Illumina). Amplicon libraries were sequenced on NextSeq500 (Illumina) at the Norwegian Sequencing Center (http://www.sequencing.uio.no).
Statistics and data analysis. Both mass cytometry and flow cytometry data were analyzed with FlowJo version 10.4 (FlowJo LLC) for visualization of data in twoparametric 2D plots (Figs. 1a,c and 2a,c,h and Extended Data Figs. 1a-d, 2, 6 , 7a,b,d,f and 10a) and for cell quantifications (Extended Data Figs. 7e,g and 10b-f) .
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We used the GraphPad Prism 7 software (GraphPad Software) for statistical analysis and visualization of cell frequencies (Fig. 1i and Extended Data Figs. 7e,g  and 10b-f) . Here, we applied an unpaired, two-tailed t-test (Extended Data  Fig. 10b ,c,e (the median frequency and interquartile range indicated)) or a paired, two-tailed t-test (Extended Data Fig. 10d,f) Mass cytometry data (the fcs file containing only blood or gut CD4 + T cells) were loaded into R using the flowCORE package. Here, the aggregate marker intensity (Figs. 1d and 2d and Extended Data Fig. 8b ) was computed as the grand mean of each donors mean marker intensity. Mass cytometry fold change (Figs. 1e and 2e,f and Extended Data Figs. 3a, 5a, 7c and 8c) was computed as the log 2 fold change of the aggregate marker intensity. Heat maps, to visualize the aggregate marker intensity and the log 2 fold change, were generated using ggplot2, and the t-SNE plots were generated using the Rtsne package. For t-SNE plots, box plots (Extended Data Figs. 3b and 5b ), supervised classification ( Fig. 2i and Extended Data Fig. 9 ) and fold-change significance testing (Supplementary Table 4) , the raw mass cytometry intensity values were first transformed using the inverse hyperbolic sine, as described by Nowicka et al. 32 . In the generated box plots in Extended Data Figs. 3b and 5b (generated with ggplot2), the y axis indicates ArcSinh-transformed intensity and the boxes show the median frequency and interquartile range. Whiskers show the largest and smallest values below 1.5 times the interquartile range. In Supplementary Table 4 , we used a paired, two-tailed t-test to calculate significant differences in the mean marker intensity between tetramer-positive and tetramer-negative cells from patients with CeD in the blood and the gut. In the same table, we performed an unpaired, two-tailed t-test for all other comparisons in which the test conditions were from unmatched donors (for example, patients with CeD versus healthy controls). P values were corrected for multiple testing using the Benjamini-Hochberg procedure.
In Fig. 2h and Extended Data Fig. 8 , we did unsupervised clustering of activated (CD38
+ T cells using the FlowSOM and ConsesusClusterPlus packages. To avoid introducing bias to the clustering and the t-SNE visualization, we had a balanced number of cells and samples per disease group. Thus, we randomly selected five samples per disease, except for gluten challenge in which we only had four samples with sufficient cells. Furthermore, we sampled at most 3,707 activated cells per sample, which is the median number of cells per sample, and used these cells for clustering. For t-SNE visualization in Fig. 2h , we subsampled 807 cells per sample, which is the number of activated cells in the smallest sample. We visualized the prevalence of cells within the two clusters (cluster 1 and cluster 2) in a box plot (Extended Data Fig. 8a ), indicating the median frequency and interquartile range. Here, the whiskers show the largest and smallest values below 1.5 times the interquartile range and single data points depict outliers. The markers used to generate the t-SNE plot in Fig. 2h and Extended Data Fig. 8 are listed in Extended Data Fig. 8b,c. We trained a supervised classification model on tetramer-positive and tetramer-negative CD4 + T cells from tetramer-enriched PBMC samples from patients with untreated CeD (Fig. 2i , with a diagram illustrating the workflow in Extended Data Fig. 9 ). The model was subsequently used to obtain an unbiased prevalence estimate of CD4 + T cells with a phenotype highly similar to the glutenspecific CD4
+ T cells in all included blood samples analyzed with mass cytometry (excluding the tetramer-enriched samples that were only used to train the model). More specifically, we used 10-fold cross-validation with three repeats to train a random forest model 33 using caret version 6.0-79. The optimal mtry parameter for the data was selected with a grid search between one and the total number of markers divided by three. Log loss was used as a metric to select the optimal model. The doMC package, version 1.3.5, was used to parallelize model training. We used the GraphPad Prism 7 software to visualize the prevalence estimates in a box plot (Fig. 2i) , which shows the median frequency and interquartile range, whereas the whiskers indicate the maximum and minimum values. Here, P values (each participant group versus the group of healthy controls) were calculated using an unpaired, two-tailed t-test. The markers used to generate the prediction model in Fig. 2i (the 22 CD4 + T cell markers that were common to the two mass cytometry staining panels in Supplementary Tables 1 and 7) are identified with two asterisks in Supplementary Table 7 . The importance function of the randomForest package was used to extract the mean decrease Gini score from the final model. A high-scoring parameter is important to the model and a low-scoring value is less relevant. This Gini score is visualized in Extended Data Fig. 9b using ggplot2 .
RNA-seq reads (76-bp paired end) were mapped to the human reference genome GRCh38.p7 containing alternative loci with gene annotations curated by Ensembl release 86 using Salmon 34 version 0.7.2 for mapping with parameters -l UI-useVBOpt-numBootStraps 30-seqBias-gcBias. The quasi-mapping index in Salmon was built using a default k-mer length of 31. Read counts of transcripts (including those on alternative loci) were aggregated to gene level. The raw sequencing data were processed on a secure computing platform; the TSD (Tjeneste for Sensitive Data) facilities owned by the University of Oslo, operated and developed by the TSD-service group. Further data processing was performed using R version 3.2 with the Bioconductor version 3.4 and the Tidyverse version 1.2.1 collection of packages. Estimated gene counts were loaded into R using Tximport. Gene differential expression analysis and log fold-change estimation (Fig. 1f-g and Extended Data Fig. 7c) were computed using DESeq2 (ref. 35 ) with a design formula controlling for sample donor. A full list of the differentially expressed genes is listed with adjusted P values in Supplementary Table 5 . Here, we used a significance threshold of 5 × 10 −3 after adjusting for multiple testing. Heat maps, to visualize the log 2 fold change, were generated using ggplot2, as with foldchange expression in the mass cytometry data.
Further information on methods, statistics and data analysis is provided in the Nature Research Reporting Summary. 
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
Flow cytometry data were collected on a LSR II instrument or a FACS Aria II cell sorter with BD FACSDiva Software, version 8. Mass cytometry data were acquired on a Helios instrument with CyTOF Software, version 6.7. RNA-seq data, amplicon libraries were sequenced on NextSeq500 (Illumina, Inc) at the Norwegian Sequencing Center (http://www.sequencing.uio.no).
Data analysis
We analyzed flow cytometry and mass cytometry data using FlowJo, version 10.4. We used the GraphPad Prism 7 software (GraphPad Software, Inc) for statistical analysis and visualization of cell frequencies. Further, mass cytometry data (fcs-files from Flowjo analysis containing only the CD4+ blood or gut T cells) were loaded into R using the flowCORE package, and visualized in heat maps, boxplots or a cell marker importance function, using ggplot2, and in t-SNE plots, using the Rtsne package. We applied the the FlowSOM and ConsesusClusterPlus packages for unsupervised clustering of activated memory CD4+ T cells. We trained a random forest model, using caret version 6.0-79, to obtain an unbiased prevalence estimate of CD4+ T cells with a phenotype highly similar to the gluten specific CD4 + T cells and the doMC package, version 1.3.5, to parallelize model training. We mapped RNA-seq reads (76 bp paired end) to the human reference genome GRCh38.p7 with gene annotations curated by Ensembl release 86, using Salmon version 0.7.2. The raw sequencing data were processed on the TSD-platform, owned by the University of Oslo. Further data processing was performed using R, version 3.2, with the Bioconductor, version 3.4, and the Tidyverse, version 1.2.1, collection of packages. Estimated gene counts were loaded into R using Tximport. We used we used DESeq2 to call differentially expressed genes and estimate fold change and ggplot2 for visualization.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. All studies must disclose on these points even when the disclosure is negative.
Sample size
Access to blood and tissue samples with a sufficient number of live cells from celiac patients, control subjects and patients with other autoimmune conditions is limited. To be able to determine test significance we chose sample size of four or more when calculating differences in cell frequencies.
Data exclusions We excluded one individual from the mass cytometry analysis and two individuals from the RNA seq analysis from the group of celiac disease patients. We recruited patients before their final diagnosis were made, and we decided to exclude these three subjects early on in the study. Two of the subjects (one for mass cytometry and one for RNA seq) were classified to have potential celiac disease (having slightly positive disease-specific serology but normal gut histology) which according to the established diagnostic guidelines is not celiac disease. We excluded one subject with celiac disease from the RNA seq analysis. On the diagnostic workup, this subject was found to have inflammation in bulbus duodeni only and not in pars descendens duodeni where the biopsies for RNA seq analysis were taken. We deemed it was important to analyze only gut biopsies of untreated celiac patients that were classified to have inflammation. We excluded a group of five patients with other autoimmune diseases (type I diabetes, hashimoto thyroeoiditis, polymyositis and mixed connective tissue disease) included in a previous version of the manuscript as per request by reviewer. The reviewer argued that this group was too small and heterogeneous to allow a meaningful interpretation. We also excluded one patient in the cohort of influenza-infected participants due to comorbidities including a clonal T-cell population consistent with large granular lymphocytic leukemia, chronic joint pains, gastritis and a small-cell B-cell lymphoma.
Replication
After establishment of the protocol, all attempts to replicate tetramer staining with mass cytometry in untreated celiac disease patients, T-cell lines and T-cell clones were successful. This was also the case for additional samples included in the revised version of the manuscript. All mass cytometry experiments were carefully controlled. A gluten-specific T-cell clone was regularly used as positive control and PBMCs from a healthy donor as a negative control and as control for the antibody panel. Pre-tetramer enriched, and tetramer-negative samples served as additional internal control samples. The number of tetramer-binding cells was lower or absent in treated celiac disease patients and controls, hence in agreement with published data using flow cytometry. In addition, results from mass cytometry, RNA seq and flow cytometry gave almost identical results, using different sets of patients and controls and finally, mass cytometry and flow cytometry results obtained at the core facilities at Stanford University could be replicated (with different patient samples), giving highly similar results at the flow core facilities at the University of Bergen and the University of Oslo, respectively.
Randomization For mass cytometry and flow cytometry analysis, we included at the same point of analysis at least one patient sample and one control sample. Potential covariates were controlled for by including the same healthy control sample to mass cytometry stainings. The RNA-seq data was acquired in two rounds. In the first round, four potential candidates for celiac disease were included (two later excluded, see above). In the second round, three celiac disease patients and four control subjects were included.
Blinding
The researchers were not blinded during data acquisition or analysis. However, in the case of celiac patients, only the serology parameters prior to referral to the hospital was known and diagnosis was given weeks after acquisition of data with mass cytometry or RNA seq.
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Clinical trial registration
Although this study involves clinical data, it it not a clinical trial. However, blood samples from five gluten challenge patients, recruited as part of a clinical trial: Clinicaltrials.gov identifier: NCT02464150, were used for mass cytometry analysis.
Study protocol
The protocols are approved by the regional ethics committees but are not publicly available. They are are available from the authors upon request
Data collection
Participants were recruited and material collected in 2015-2017 in locations as described above (see 'recruitment'). Samples were analyzed in 2016-2018 at The Human Immune Monitoring Center (Stanford University), the Flow Cytometry Core Facility at Oslo University Hospital -Rikshospitalet and Radiumhospitalet, the Flow Core Facility at the University of Bergen, the Institute for Immunity, Transplantation and Infection at Stanford University School of Medicine and at the Department of Immunology (Oslo University Hospital and Univeristy of Oslo).
Outcomes
In the study we used clinical data. However, outcomes were not predefined as in a clinical trial.
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All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
These steps are described in detail in the manuscript's Online Methods. For flow cytometry studies, PBMCs were separated from blood with Lymphoprep according to the manufacturer's protocol and single-cell suspensions were generated from duodenal biopsies using 1% collagenase. Cell samples were frozen in 10% DMSO and later thawed in 20% FCS/RPMI. The samples were then stained with Fc receptor blocker on ice followed by HLA-DQ2.5:gluten tetramers or HLA-DQ8: gluten tetramers for 40 minutes at room temperature. In the case of tetramer-stained blood samples, these were stained with anti-PE antibody-coated magnetic beads for 20 minutes on ice and then enriched on a magnetized LS column (Miltenyi Biotec) to increase the frequency of tetramer-binding cells within the cell sample. The samples were then stained with live/dead staining according to manufacturer's protocol and then on ice for 20 minutes with a cocktail of cell surface antibodies. Staining of intracellular Ki-67 and FoxP3 was done subsequently according to the manufacturer's protocol. See the Online Methods section of this paper for details on mass cytometry staining.
Instrument
We used either a LSR II instrument or a FACS Aria II cell sorter. Mass cytometry data were acquired on a Helios instrument.
Software
Flow cytometry data were analyzed with FlowJo version 10.4. Mass cytometry data were analyzed with FlowJo version 10.4 to exclude cells that were not CD4+ T cells followed by analysis R using different packages specified by name and version in the methods section of this paper and in this Reporting Summary (see "Software and Code").
Cell population abundance Tetramer-sorted and in vitro cultured T-cell lines and T-cell clones were purity checked thorough re-staining with the relevant tetramers after in vitro culturing. Purity of cells sorted for RNA seq was not checked after sorting due to the low number of obtained cells.
Gating strategy
For mass cytometry, the gating strategy is visualized in Extended Data Fig. 2 and for the calculation of the frequency of cells with the phenotype of gluten-specific CD4+ T cells, in Extended Data Fig. 10a . For flow cytometry, we used the following gating procedure: Forward scatter vs forward scatter width; forward scatter vs side scatter; Dump (CD11c, CD14, CD19, CD56 and live/ dead) vs CD3; CD4; CD4 vs tetramer. We included the gating strategy for flow cytometry in Extended Data Fig. 6 .
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
